Table 1 Characteristics of the patients
BP + VD (n = 42) | Other treatments (n = 75) | p value | |
|---|---|---|---|
Demographics | |||
Female, n (%) | 35 (83%) | 69 (92%) | 0.22 |
Age (years) | 40 (31, 49) | 43 (35, 54) | 0.18 |
Age at diagnosis (years) | 32.5 (21, 43) | 28 (19, 40) | 0.19 |
Smoking, n (%) | 16 (38%) | 28 (43%) | 0.59 |
Post menopause, n (%) | 13/35 (37%) | 30/69 (43%) | 0.56 |
BMI (kg/m2) | 22.3 (20.1, 24.1) | 22.1 (19.2, 26.0) | 0.56 |
Duration of disease (years) | 5 (0, 13) | 12 (5, 24) | < 0.001 |
SLEDAI-2 K | 5 (2, 13) | 4 (2, 6) | 0.07 |
History of LN, n (%) | 20 (48%) | 31 (41%) | 0.51 |
APS, n (%) | 10 (24%) | 14 (19%) | 0.47 |
Diabetes mellitus, n (%) | 9 (21%) | 17 (23%) | 0.88 |
Hypertension, n (%) | 26 (62%) | 45 (60%) | 0.84 |
Systolic blood pressure (mmHg) | 119 (110, 130) | 121 (111, 132) | 0.59 |
Diastolic blood pressure (mmHg) | 74 (69, 82) | 77 (70, 86) | 0.25 |
Dyslipidemia, n (%) | 32 (76%) | 50(67%) | 0.28 |
Total cholesterol (mg/dL) | 194 (160, 226) | 199 (172, 220) | 0.51 |
Triglyceride (mg/dL) | 130 (95, 185) | 147 (94, 209) | 0.39 |
HDL-C (mg/dL) | 61 (42, 76) | 64 (52, 75) | 0.25 |
LDL-C (mg/dL) | 99 (86, 131) | 101 (83, 124) | 0.87 |
CKD, n (%) | 20 (48%) | 32 (43%) | 0.65 |
eGFR (mL/min) | 79.1 (24.8) | 74.1 (25.8) | 0.31 |
Serum creatinine (mg/dL) | 0.7 (0.60, 0.88) | 0.68 (0.59, 0.87) | 0.98 |
aPL, n (%) | 17 (40%) | 25 (33%) | 0.44 |
History of CVD, n (%) | 6 (14%) | 5 (7%) | 0.20 |
History of bone fractures, n (%) | 5 (12%) | 9 (12%) | 1.00 |
BMD measurements | |||
BMD (lumbar spine) (g/cm2) | 0.975 (0.159) | 0.990 (0.180) | 0.68 |
BMD (FN) (g/cm2) | 0.717 (0.151) | 0.708 (0.117) | 0.61 |
Low BMD, n (%) | 25/38 (66%) | 23/63 (37%) | 0.004 |
Osteoporosis, n (%) | 4/38 (12%) | 5/63 (12%) | 0.73 |
Carotid measurements | |||
Carotid plaque, n (%) | 7 (17%) | 33 (44%) | 0.002 |
Mean IMT (mm) | 0.56 (0.12) | 0.61 (0.17) | 0.07 |
Treatment | |||
Duration of anti-osteoporotic treatment (months) | 47 (3, 72) | 47 (26, 65) | 0.89 |
Cumulative dose of GC (ga) | 37.2 (4.5, 86.2) | 74.3 (23.4, 118.3) | 0.028 |
Duration of GC use (months) | 80 (2, 166) | 164 (47, 276) | 0.002 |
Current dose of GC (mga/day) | 16 (9, 30) | 7.5 (5, 10) | < 0.001 |
Concomitant use of IS, n (%) | 29 (69%) | 41 (55%) | 0.12 |
mPSL pulse, n (%) | 23 (55%) | 28 (38%) | 0.079 |
Maximum dose of oral GC (mga/day) | 60 (40, 60) | 60 (30, 60) | 0.38 |
Antihypertensive agent, n (%) | 25 (60%) | 36 (48%) | 0.23 |
Statin, n (%) | 24 (57%) | 29 (39%) | 0.054 |